Molecular and clinical evidence for the unique nature of individual selective estrogen receptor modulators

Clinical Obstetrics and Gynecology

Volumn 46, Issue 2, 2003, Pages 265-297

  Draper, Michael W ^a,b   Chin, William W ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,1,2 TRIPHENYLETHYLENE DERIVATIVE; 4 [4 METHYL 2 [4 [2 (1 PIPERIDINYL)ETHOXY]PHENYL] 7 PIVALOYLOXY 2H 1 BENZOPYRAN 3 YLPHENYL] PIVALATE; ARZOXIFENE; BAZEDOXIFENE; BENZOTHIOPHENE DERIVATIVE; CENTCHROMAN; CLOMIFENE; CONJUGATED ESTROGEN; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; CP 336 156; DROLOXIFENE; ENCLOMIFENE; ESTRADIOL; ESTRADIOL VALERATE; ESTROGEN; FULVESTRANT; GESTAGEN; GESTODENE; IDOXIFENE; INDOLE DERIVATIVE; LASOFOXIFENE; MIPROXIFENE PHOSPHATE; N BUTYL 11 (3,17BETA DIHYDROXYESTRA 1,3,5(10) TRIEN 7ALPHA YL) N METHYLUNDECANAMIDE; NAPHTHALENE DERIVATIVE; NNC 46 0020; NORETHISTERONE ACETATE; OSPEMIFENE; PHYTOESTROGEN; PIPENDOXIFENE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TOREMIFENE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZUCLOMIFENE;

ARTERY DISEASE; BREAST CANCER; CANCER PREVENTION; CANCER RISK; CLINICAL TRIAL; DRUG ANTAGONISM; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; EMBOLISM; ESTROGEN RESPONSIVE ELEMENT; EYE DISEASE; GENE EXPRESSION REGULATION; HEART PROTECTION; HORMONAL THERAPY; HUMAN; LEG CRAMP; MENOPAUSAL SYNDROME; META ANALYSIS; MOLECULAR MECHANICS; NONHUMAN; OSTEOPOROSIS; OVULATION; REVIEW; RNA TRANSLATION; TRANSACTIVATION; TRANSCRIPTION REGULATION; TREATMENT OUTCOME; VASOMOTOR DISORDER; VEIN THROMBOSIS;

FEMALE; HUMANS; PROTEIN ISOFORMS; RECEPTORS, ESTROGEN; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 0038826193     PISSN: 00099201     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003081-200306000-00008     Document Type: Review

References (226)

1. Baker VL, Leitman D, Jaffe RB. Selective estrogen receptor modulators in reproductive medicine and biology. Obstet Gynecol Surv. 2000;55:S21-S47.
2. Dutertre M, Smith CL. Molecular mechanisms of selective estrogen receptor modulator (SERM) action. J Pharmacol Exp Ther. 2000;295:431-437.
3. Katzenellenbogen BS, Katzenellenbogen JA. Estrogen receptor transcription and transactivation: Estrogen receptor alpha and estrogen receptor beta: regulation by selective estrogen receptor modulators and importance in breast cancer. Breast Cancer Res. 2000;2:335-344.
4. Katzenellenbogen BS, Choi I, Delage-Mourroux R, et al. Molecular mechanisms of estrogen action: selective ligands and receptor pharmacology. J Steroid Biochem Mol Biol. 2000;74:279-285.
5. Lonard DM, Smith CL. Molecular perspectives on selective estrogen receptor modulators (SERMs): progress in understanding their tissue-specific agonist and antagonist actions. Steroids. 2002;67:15-24.
6. McDonnell DP, Wijayaratne A, Chang CY, Norris JD. Elucidation of the molecular mechanism of action of selective estrogen receptor modulators. Am J Cardiol. 2002;90:35F-43F.
7. McKenna NJ, O'Malley BW. An issue of tissues: divining the split personalities of selective estrogen receptor modulators. Nat Med. 2000;6:960-962.
8. Osborne CK, Zhao H, Fuqua SA. Selective estrogen receptor modulators: structure, function, and clinical use. J Clin Oncol. 2000;18:3172-3186.
9. Smith CL, O'Malley BW. Evolving concepts of selective estrogen receptor action: from basic science to clinical applications. Trends Endocrinol Metab. 1999;10:299-300.
10. Riggs BL, Hartmann LC. Selective estrogen-receptor modulators: mechanisms of action and application to clinical practice. N Engl J Med. 2003;348:618-629.
11. Jordan VC. Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 2. Clinical considerations and new agents. J Med Chem. 2003;46:1081-1111.
12. Nilsson S, Makela S, Treuter E, et al. Mechanisms of estrogen action. Physiol Rev. 2001;81:1535-1565.
13. Bryant HU. Mechanism of action and preclinical profile of raloxifene, a selective estrogen receptor modulation. Rev Endocr Metab Disord. 2001;2:129-138.
14. Diel P. Tissue-specific estrogenic response and molecular mechanisms. Toxicol Lett. 2002;127:217-224.
15. Grese TA, Dodge JA. Selective estrogen receptor modulators (SERMs). Curr Pharm Des. 1998;4:71-92.
16. Katzenellenbogen BS, Sun J, Harrington WR, et al. Structure-function relationships in estrogen receptors and the characterization of novel selective estrogen receptor modulators with unique pharmacological profiles. Ann NY Acad Sci. 2001;949:6-15.
17. Krishnan V, Heath H, Bryant HU. Mechanism of action of estrogens and selective estrogen receptor modulators. Vitam Horm. 2000;60:123-147.
18. Emmen JM, Korach KS. Developing animal models for analyzing SERM activity. Ann NY Acad Sci. 2001;949:36-43.
19. Liu MM, Albanese C, Anderson CM, et al. Opposing action of estrogen receptors alpha and beta on cyclin D1 gene expression. J Biol Chem. 2002;277:24353-24360.
20. Paige LA, Christensen DJ, Gron H, et al. Estrogen receptor (ER) modulators each induce distinct conformational changes in ER alpha and ER beta. Proc Natl Acad Sci USA. 1999;96:3999-4004.
21. Price RH Jr, Butler CA, Webb P, et al. A splice variant of estrogen receptor beta missing exon 3 displays altered subnuclear localization and capacity for transcriptional activation. Endocrinology. 2001;142:2039-2049.
22. Cowley SM, Hoare S, Mosselman S, Parker MG. Estrogen receptors alpha and beta form heterodimers on DNA. J Biol Chem. 1997;272:19858-19862.
23. Wood JR, Greene GL, Nardulli AM. Estrogen response elements function as allosteric modulators of estrogen receptor conformation. Mol Cell Biol. 1998;18:1927-1934.
24. Heery DM, Kalkhoven E, Hoare S, Parker MG. A signature motif in transcriptional co-activators mediates binding to nuclear receptors. Nature. 1997;387:733-736.
25. McInerney EM, Katzenellenbogen BS. Different regions in activation function-1 of the human estrogen receptor required for antiestrogen- and estradiol-dependent transcription activation. J Biol Chem. 1996;271:24172-24178.
26. Shang Y, Hu X, DiRenzo J, et al. Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription. Cell. 2000;103:843-852.
27. Webb P, Nguyen P, Shinsako J, et al. Estrogen receptor activation function 1 works by binding p 160 coactivator proteins. Mol Endocrinol. 1998;12:1605-1618.
28. Planas-Silva MD, Shang Y, Donaher JL, et al. AIB1 enhances estrogen-dependent induction of cyclin D1 expression. Cancer Res. 2001;61:3858-3862.
29. Fan S, Ma YX, Wang C, et al. p300 Modulates the BRCA1 inhibition of estrogen receptor activity. Cancer Res. 2002;62:141-151.
30. McMahon C, Suthiphongchai T, DiRenzo J, Ewen ME. P/CAF associates with cyclin D1 and potentiates its activation of the estrogen receptor. Proc Natl Acad Sci USA. 1999;96:5382-5387.
31. Belandia B, Orford RL, Hurst HC, Parker MG. Targeting of SWI/SNF chromatin remodeling complexes to estrogen-responsive genes. EMBO J. 2002;21:4094-4103.
32. Smith CL, Nawaz Z, O'Malley BW. Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen. Mol Endocrinol. 1997;11:657-666.
33. Zajchowski DA, Kauser K, Zhu D, et al. Identification of selective estrogen receptor modulators by their gene expression fingerprints. J Biol Chem. 2000;275:15885-15894.
34. Shang Y, Brown M. Molecular determinants for the tissue specificity of SERMs. Science. 2002;295:2465-2468.
35. Brzozowski AM, Pike AC, Dauter Z, et al. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature. 1997;389:753-758.
36. Pissios P, Tzameli I, Kushner P, Moore DD. Dynamic stabilization of nuclear receptor ligand binding domains by hormone or corepressor binding. Mol Cell. 2000;6:245-253.
37. Shiau AK, Barstad D, Loria PM, et al. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell. 1998;95:927-937.
38. Hubbard RE, Pike AC, Brzozowski AM, et al. Structural insights into the mechanisms of agonism and antagonism in oestrogen receptor isoforms. EJC. 2000;36(Suppl 4):S17-S18.
39. Gee AC, Katzenellenbogen JA. Probing conformational changes in the estrogen receptor: evidence for a partially unfolded intermediate facilitating ligand binding and release. Mol Endocrinol. 2001;15:421-428.
40. Kraichely DM, Sun J, Katzenellenbogen JA, Katzenellenbogen BS. Conformational changes and coactivator recruitment by novel ligands for estrogen receptor-alpha and estrogen receptor-beta: correlations with biologic character and distinct differences among SRC coactivator family members. Endocrinology. 2000;141:3534-3545.
41. Norris JD, Paige LA, Christensen DJ, et al. Peptide antagonists of the human estrogen receptor. Science. 1999;285:744-746.
42. Mak HY, Hoare S, Henttu PM, Parker MG. Molecular determinants of the estrogen receptor-coactivator interface. Mol Cell Biol. 1999;19:3895-3903.
43. Shiau AK, Barstad D, Radek JT, et al. Structural characterization of a subtype-selective ligand reveals a novel mode of estrogen receptor antagonism. Nat Struct Biol. 2002;9:359-364.
44. Webb P, Nguyen P, Valentine C, et al. The estrogen receptor enhances AP-1 activity by two distinct mechanisms with different requirements for receptor transactivation functions. Mol Endocrinol. 1999;13:1672-1685.
45. Kushner PJ, Agard DA, Greene GL, et al. Estrogen receptor pathways to AP-1. J Steroid Biochem Mol Biol. 2000;74:311-317.
46. Ignar-Trowbridge DM, Pimentel M, Parker MG, et al. Peptide growth factor cross-talk with the estrogen receptor requires the A/B domain and occurs independently of protein kinase C or estradiol. Endocrinology. 1996;137:1735-1744.
47. Feng W, Webb P, Nguyen P, et al. Potentiation of estrogen receptor activation function 1 (AF-1) by Src/JNK through a serine 118-independent pathway. Mol Endocrinol. 2001;15:32-45.
48. Power RF, Mani SK, Codina J, et al. Dopaminergic and ligand-independent activation of steroid hormone receptors. Science. 1991;254:1636-1639.
49. Simoncini T, Hafezi-Moghadam A, Brazil DP, et al. Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature. 2000;407:538-541.
50. Simoncini T, Genazzani AR, Liao JK. Nongenomic mechanisms of endothelial nitric oxide synthase activation by the selective estrogen receptor modulator raloxifene. Circulation. 2002;105:1368-1373.
51. Razandi M, Pedram A, Greene GL, Levin ER. Cell membrane and nuclear estrogen receptors (ERs) originate from a single transcript: studies of ER-alpha and ER-beta expressed in Chinese hamster ovary cells. Mol Endocrinol. 1999;13:307-319.
52. Kousteni S, Bellido T, Plotkin LI, et al. Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity. Cell. 2001;104:719-730.
53. Herrington DM, Reboussin DM, Brosnihan KB, et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med. 2000;343:522-529.
54. Krauss RM. Individualized hormone-replacement therapy? N Engl J Med. 2002;346:1017-1018.
55. Morello KC, Wurz GT, DeGregorio MW. SERMs: current status and future trends. Crit Rev Oncol Hematol. 2002;43:63-76.
56. Speroff L, Symons J, Kempfert N, Rowan J. The effect of varying low-dose combinations of norethindrone acetate and ethinyl estradiol (FemHRT) on the frequency and intensity of vasomotor symptoms. Menopause. 2000;7:383-390.
57. Mattox JH, Shulman LP. Combined oral hormone replacement therapy formulations. Am J Obstet Gynecol. 2001;185(Suppl 46).
58. Utian WH, Shoupe D, Bachmann G, et al. Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate. Fertil Steril. 2001;75:1065-1079.
59. Barnabei VM, Grady D, Stovall DW, et al. Menopausal symptoms in older women and the effects of treatment with hormone therapy. Obstet Gynecol. 2002;100:1209-1218.
60. Shulman LP. Effects of progestins in different hormone replacement therapy formulations on estrogen-induced lipid changes in postmenopausal women. Am J Cardiol. 2002;89:47E-54E.
61. Wellington K, Perry CM. Estradiol valerate/dienogest. Drugs. 2002;62:491-504.
62. Alexandersen P, Byrjalsen I, Christiansen C. Piperazine oestrone sulphate and interrupted norethisterone in postmenopausal women: effects on bone mass, lipoprotein metabolism, climacteric symptoms, and adverse effects. Br J Obstet Gynecol. 2000;107:356-364.
63. Panay N, Zamblera D, Sands R, et al. Low-dose 25-mg oestradiol implants and 1-mg norethisterone as continuous combined hormone therapy: a prospective study. Br J Obstet Gynecol. 2002;109:958-960.
64. Paoletti AM, Pilloni M, Orru M, et al. Efficacy and safety of oral and transdermal hormonal replacement treatment containing levonorgestrel. Maturitas. 2002;42:137-147.
65. Taechakraichana N, Limpaphayom K, Ninlagarn T, et al. A randomized trial of oral contraceptive and hormone replacement therapy on bone mineral density and coronary heart disease risk factors in postmenopausal women. Obstet Gynecol. 2000;95:87-94.
66. Morabito N, Crisafulli A, Vergara C, et al. Effects of Genistein and hormone replacement therapy on bone loss in early postmenopausal women: a randomized double-blind placebo-controlled study. J Bone Miner Res. 2002;17:1904-1912.
67. Lucas EA, Wild RD, Hammond LJ, et al. Flaxseed improves lipid profile without altering biomarkers of bone metabolism in postmenopausal women. J Clin Endocrinol Metab. 2002;87:1527-1532.
68. Stark A, Madar Z. Phytoestrogens: a review of recent findings. J Pediatr Endocrinol Metab. 2002;15:561-572.
69. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA. 1998;280:605-613.
70. Grady D, Herrington D, Bittner V, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA. 2002;288:49-57.
71. Hulley S, Furberg C, Barrett-Connor E, et al. Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA. 2002;288:58-66.
72. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321-333.
73. Barrett-Connor E, Grady D. Hormone replacement therapy, heart disease, and other considerations. Ann Rev Public Health. 1998;19:55-72.
74. Grady D, Hulley SB. Hormones to prevent coronary disease in women: when are observational studies adequate evidence? Ann Intern Med. 2000;133:999-1001.
75. Viscoli CM, Brass LM, Kernan WN, et al. A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med. 2001;345:1243-1249.
76. Tolbert T, Oparil S. Hormone replacement therapy and stroke: are the results surprising? Circulation. 2001;103:620-622.
77. Simon JA, Hsia J, Cauley JA, et al. Postmenopausal hormone therapy and risk of stroke: The Heart and Estrogen-progestin Replacement Study (HERS). Circulation. 2001;103:638-642.
78. Hsia J, Simon JA, Lin F, et al. Peripheral arterial disease in randomized trial of estrogen with progestin in women with coronary heart disease: the Heart and Estrogen/Progestin Replacement Study. Circulation. 2000;102:2228-2232.
79. Cherry N, Gilmour K, Hannaford P, et al. Oestrogen therapy for prevention of reinfarction in postmenopausal women: a randomised placebo controlled trial. Lancet. 2002;360:2001-2008.
80. Schulman SP, Thiemann DR, Ouyang P, et al. Effects of acute hormone therapy on recurrent ischemia in postmenopausal women with unstable angina. J Am Coll Cardiol. 2002;39:231-237.
81. Waters DD, Alderman EL, Hsia J, et al. Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women: a randomized controlled trial. JAMA. 2002;288:2432-2440.
82. Angerer P, Stork S, Kothny W, et al. Effect of oral postmenopausal hormone replacement on progression of atherosclerosis: a randomized, controlled trial. Arteriosclerosis Thromb Vasc Biol. 2001;21:262-268.
83. Angerer P, Stork S, Kothny W, von Schacky C. Effect of postmenopausal hormone replacement on atherosclerosis in femoral arteries. Maturitas. 2002;41:51-60.
84. Hodis HN, Mack WJ, Lobo RA, et al. Estrogen in the prevention of atherosclerosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2001;135:939-953.
85. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA. 1995;273:199-208.
86. Walsh BW, Paul S, Wild RA, et al. The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab. 2000;85:214-218.
87. Walsh BW, Kuller LH, Wild RA, et al. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. [comment]. JAMA. 1998;279:1445-1451.
88. Nickelsen T, Creatsas G, Rechberger T, et al. Differential effects of raloxifene and continuous combined hormone replacement therapy on biochemical markers of cardiovascular risk: results from the Euralox 1 study. Climacteric. 2001;4:320-331.
89. Prelevic GM, Kwong P, Byrne DJ, et al. A cross-sectional study of the effects of replacement therapy on the cardiovascular disease risk profile in healthy postmenopausal women. Fertil Steril. 2002;77:945-951.
90. Nieto JJ, Cogswell D, Jesinger D, Hardiman P. Lipid effects of hormone replacement therapy with sequential transdermal 17-beta-estradiol and oral dydrogesterone. Obstet Gynecol. 2000;95:111-114.
91. Cushman M. Effects of hormone replacement therapy and estrogen receptor modulators on markers of inflammation and coagulation. Am J Cardiol. 2002;90:7F-10F.
92. Cauley JA, Black DM, Barrett-Connor E, et al. Effects of hormone replacement therapy on clinical fractures and height loss: The Heart and Estrogen/Progestin Replacement Study (HERS). Am J Med. 2001;110:442-450.
93. Lindsay R, Gallagher JC, Kleerekoper M, Pickar JH. Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women. JAMA. 2002;287:2668-2676.
94. Nelson HD, Rizzo J, Harris E, et al. Osteoporosis and fractures in postmenopausal women using estrogen. Arch Intern Med. 2002;162:2278-2284.
95. Wells G, Tugwell P, Shea B, et al. Meta-analyses of therapies for postmenopausal osteoporosis. V. Meta-analysis of the efficacy of hormone replacement therapy in treating and preventing osteoporosis in postmenopausal women. Endocrin Rev. 2002;23:529-539.
96. Torgerson DJ, Bell-Syer SE. Hormone replacement therapy and prevention of nonvertebral fractures: a meta-analysis of randomized trials. JAMA. 2001;285:2891-2897.
97. Michaelsson K, Baron JA, Farahmand BY, Ljunghall S. Use of low-potency estrogens does not reduce the risk of hip fracture. Bone. 2002;30:613-618.
98. Margerison C, Paton LM, Nowson CA, et al. Hormone replacement therapy and bone mineral density: a co-twin approach. Menopause. 2002;9:436-442.
99. Gambacciani M, Monteleone P, Genazzani AR. Low-dose hormone replacement therapy: effects on bone. Climacteric. 2002;5:135-139.
100. Arjmandi BH, Smith BJ. Soy isoflavones' osteoprotective role in postmenopausal women: mechanism of action. J Nutr Biochem. 2002;13:130-137.
101. Notelovitz M, John VA, Good WR. Effectiveness of Alora estradiol matrix transdermal delivery system in improving lumbar bone mineral density in healthy, postmenopausal women. Menopause. 2002;9:343-353.
102. Archer DF, Dorin M, Lewis V, et al. Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on endometrial bleeding. Fertil Steril. 2001;75:1080-1087.
103. Riman T, Dickman PW, Nilsson S, et al. Hormone replacement therapy and the risk of invasive epithelial ovarian cancer in Swedish women. J Natl Cancer Inst. 2002;94:497-504.
104. Grady D, Brown JS, Vittinghoff E, et al. Postmenopausal hormones and incontinence: the Heart and Estrogen/Progestin Replacement Study. Obstet Gynecol. 2001;97:116-120.
105. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. [Erratum appears in Lancet. 1997;350:1484]. Lancet. 1997;350:1047-1059.
106. Chen CL, Weiss NS, Newcomb P, et al. Hormone replacement therapy in relation to breast cancer. JAMA. 2002;287:734-741.
107. Weiss LK, Burkman RT, Cushing-Haugen KL, et al. Hormone replacement therapy regimens and breast cancer risk. Obstet Gynecol. 2002;100:1148-1158.
108. Santen RJ, Pinkerton J, McCartney C, Petroni GR. Risk of breast cancer with progestins in combination with estrogen as hormone replacement therapy. J Clin Endocrinol Metab. 2001;86:16-23.
109. Ross RK, Paganini-Hill A, Wan PC, Pike MC. Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst. 2000;92:328-332.
110. Schairer C, Lubin J, Troisi R, et al. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. [Erratum appears in JAMA. 2000;284:2597]. JAMA. 2000;283:485-491.
111. McEwen B. Estrogen actions throughout the brain. Recent Prog Horm Res. 2002;57:357-384.
112. LeBlanc ES, Janowsky J, Chan BK, Nelson HD. Hormone replacement therapy and cognition: systematic review and meta-analysis. JAMA. 2001;285:1489-1499.
113. Yaffe K. Estrogens, selective estrogen receptor modulators, and dementia: what is the evidence? Ann NY Acad Sci. 2001;949:215-222.
114. Cholerton B, Gleason CE, Baker LD, Asthana S. Estrogen and Alzheimer's disease: the story so far. Drugs Aging. 2002;19:405-427.
115. Seshadri S, Zornberg GL, Derby LE, et al. Postmenopausal estrogen replacement therapy and the risk of Alzheimer disease. Arch Neurol. 2001;58:435-440.
116. Mulnard RA, Cotman CW, Kawas C, et al. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer's Disease Cooperative Study. [Erratum appears in JAMA. 2000;284:2597]. JAMA. 2000;283:1007-1015.
117. Adashi EY. Ovulation induction: clomiphene citrate. In Adashi EY, Rock JA, Rosenwaks Z (eds), Reproductive Endocrinology, Surgery and Technology. Lippincott-Raven, Philadelphia, 1996, pp. 1181-1206.
118. Sereepapong W, Suwajanakorn S, Triratanachat S, et al. Effects of clomiphene citrate on the endometrium of regularly cycling women. Fertil Steril. 2000;73:287-291.
119. Triwitayakorn A, Suwajanakorn S, Triratanachat S, et al. Effects of initiation day of clomiphene citrate on the endometrium of women with regular menstrual cycles. Fertil Steril. 2002;78:102-107.
120. Johnston SR. Endocrine manipulation in advanced breast cancer: recent advances with SERM therapies. Clin Cancer Res. 2001;7:4376S-4387S.
121. Clemons M, Danson S, Howell A. Tamoxifen (Nolvadex): a review. Cancer Treat Rev. 2002;28:165-180.
122. Reis SE, Costantino JP, Wickerham DL, et al. Cardiovascular effects of tamoxifen in women with and without heart disease: breast cancer prevention trial. National Surgical Adjuvant Breast and Bowel Project Breast Cancer Prevention Trial Investigators. J Natl Cancer Inst. 2001;93:16-21.
123. Liberopoulos E, Karabina SA, Tselepis A, et al. Are the effects of tamoxifen on the serum lipid profile modified by apolipoprotein E phenotypes? Oncology. 2002;62:115-120.
124. Mastroianni A, Bellati C, Facchetti G, et al. Increased plasma HDL-cholesterol and apo A-I in breast cancer patients undergoing adjuvant tamoxifen therapy. Clin Biochem. 2000;33:513-516.
125. Simon T, Boutouyrie P, Simon JM, et al. Influence of tamoxifen on carotid intimamedia thickness in postmenopausal women. Circulation. 2002;106:2925-2929.
126. Ong PJ, Linardou H, Graham HA, et al. Tamoxifen is not detrimental to endothelial function in postmenopausal women with breast cancer. Am Heart J. 2001;142:E6.
127. Yoneda K, Tanji Y, Ikeda N, et al. Influence of adjuvant tamoxifen treatment on bone mineral density and bone turnover markers in postmenopausal breast cancer patients in Japan. Cancer Lett. 2002;186:223.
128. Powles TJ, Hickish T, Kanis JA, et al. Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol. 1996;14:78-84.
129. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998;90:1371-1388.
130. Pukkala E, Kyyronen P, Sankila R, Holli K. Tamoxifen and toremifene treatment of breast cancer and risk of subsequent endometrial cancer: a population-based case-control study. Int J Cancer. 2002;100:337-341.
131. Bergman L, Beelen ML, Gallee MP, et al. Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres ALERT Group: Assessment of Liver and Endometrial Cancer Risk following Tamoxifen. Lancet. 2000;356:881-887.
132. Goldstein SR. The effect of SERMs on the endometrium. Ann NY Acad Sci. 2001;949:237-242.
133. Cuzick J, Powles T, Veronesi U, et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet. 2003;361:296-300.
134. Mourits MJ, De Vries EG, Willemse PH, et al. Tamoxifen treatment and gynecologic side effects: a review. Obstet Gynecol. 2001;97:855-866.
135. Ali S, Coombes RC. Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Cancer. 2002;2:101-112.
136. Pritchard KI. Breast cancer prevention with selective estrogen receptor modulators: a perspective. Ann NY Acad Sci. 2001;949:89-98.
137. Wolmark N, Dunn BK. The role of tamoxifen in breast cancer prevention: issues sparked by the NSABP Breast Cancer Prevention Trial (P-1). Ann NY Acad Sci. 2001;949:99-108.
138. Heinig A, Lampe D, Kolbl H, et al. Suppression of unspecific enhancement on breast magnetic resonance imaging (MRI) by antiestrogen medication. Tumori. 2002;88:215-223.
139. Palomares MR, Pratt KD, Machia JR, et al. Tamoxifen modifies mammographic density, a noninvasive marker of breast cancer risk. Breast Cancer Res Treat. 2001;69:225.
140. Ernst T, Chang L, Cooray D, et al. The effects of tamoxifen and estrogen on brain metabolism in elderly women. J Natl Cancer Inst. 2002;94:592-597.
141. Paganini-Hill A, Clark LJ. Preliminary assessment of cognitive function in breast cancer patients treated with tamoxifen. Breast Cancer Res Treat. 2000;64:165-176.
142. Benson JR. Re: The effects of tamoxifen and estrogen on brain metabolism in elderly women. J Natl Cancer Inst. 2002;94:1336-1337.
143. Cook LS, Weiss NS, Pharris-Ciurej N, et al. Colorectal cancer following tamoxifen therapy for breast cancer (United States). Cancer Causes Control. 2001;12:405-410.
144. Herrington DM, Brosnihan KB, Pusser BE, et al. Differential effects of E and droloxifene on C-reactive protein and other markers of inflammation in healthy postmenopausal women. J Clin Endocrinol Metab. 2001;86:4216-4222.
145. Miller CP, Harris HA, Komm BS. Bazedoxifene acetate. Drugs of the Future. 2002;27:117-121.
146. Hendrix SL, McNeeley SG. Effect of selective estrogen receptor modulators on reproductive tissues other than endometrium. Ann NY Acad Sci. 2001;949:243-250.
147. Buzdar A, Hayes D, El Khoudary A, et al. Phase III randomized trial of droloxifene and tamoxifen as first-line endocrine treatment of ER/PgR-positive advanced breast cancer. Breast Cancer Res Treat. 2002;73:161-175.
148. Geisler J, Ekse D, Hosch S, Lonning PE. Influence of droloxifene (3-hydroxytamoxifen), 40 mg daily, on plasma gonadotrophins, sex hormone binding globulin and estrogen levels in postmenopausal breast cancer patients. J Steroid Biochem Mol Biol. 1995;55:193-195.
149. Fleischer AC, Wheeler JE, Yeh IT, et al. Sonographic assessment of the endometrium in osteopenic postmenopausal women treated with idoxifene. J Ultrasound Med. 1999;18:503-512.
150. Delmas PD, Garnero P, MacDonald B. Idoxifene reduces bone turnover in osteopenic postmenopausal women. Bone. 1998;23(Suppl.):S494.
151. Mulder H, Wasnich R, Eastell R, et al. The effects of idoxifene on markers of cardiovascular risk in osteopenic postmenopausal women. Eur Heart J. 1998;19 (Suppl):237.
152. Chesnut C, Weiss S, Mulder H, et al. Idoxifene increases bone mineral density in osteopenic postmenopausal women. Bone. 1998;23(Suppl.):S389.
153. Maenpaa J, Holli K, Pasanen T. Toremifene: where do we stand? EJC. 2000;36:S61.
154. Joensuu H, Holli K, Oksanen H, Valavaara R. Serum lipid levels during and after adjuvant toremifene or tamoxifen therapy for breast cancer. Breast Cancer Res Treat. 2000;63:225-234.
155. Saarto T, Blomqvist C, Ehnholm C, et al. Antiatherogenic effects of adjuvant antiestrogens: a randomized trial comparing the effects of tamoxifen and toremifene on plasma lipid levels in postmenopausal women with node-positive breast cancer. J Clin Oncol. 1996;14:429-433.
156. Marttunen MB, Hietanen P, Tiitinen A, Ylikorkala O. Comparison of effects of tamoxifen and toremifene on bone biochemistry and bone mineral density in postmenopausal breast cancer patients. J Clin Endocrinol Metab. 1998;83:1158-1162.
157. Holli K, Valavaara R, Blanco G, et al. Safety and efficacy results of a randomized trial comparing adjuvant toremifene and tamoxifen in postmenopausal patients with node-positive breast cancer. Finnish Breast Cancer Group. J Clin Oncol. 2000;18:3487-3494.
158. Pyrhonen S, Ellmen J, Vuorinen J, et al. Meta-analysis of trials comparing toremifene with tamoxifen and factors predicting outcome of antiestrogen therapy in postmenopausal women with breast cancer. Breast Cancer Res Treat. 1999;56:133-143.
159. Holli K. Tamoxifen versus toremifene in the adjuvant treatment of breast cancer. EJC. 2002;38(Suppl 6):S37-S38.
160. Shibutani S, Ravindernath A, Terashima I, et al. Mechanism of lower genotoxicity of toremifene compared with tamoxifen. Cancer Res. 2001;61:3925-3931.
161. Hirsimaki P, Aaltonen A, Mantyla E. Toxicity of antiestrogens. Breast J. 2002;8:92-96.
162. Howell A. Tamoxifen versus the newer SERMs: what is the evidence? Ann Oncol. 2000;11 (Suppl 3):255-265.
163. DeGregorio MW, Wurz GT, Taras TL, et al. Pharmacokinetics of (deaminohydroxy) toremifene in humans: a new, selective estrogen-receptor modulator. Eur J Clin Pharmacol. 2000;56:469-475.
164. Erkkola RS, Halonen K, Heikkinen J, et al. Comparison of FC1271a, a novel SERM, and raloxifene in postmenopausal women: A 12-week clinical phase II study. 11th International Congress of Endocrinology, 2000.
165. Voipio SK, Komi J, Kangas L, et al. Effects of ospemifene (FC-1271a) on uterine endometrium, vaginal maturation index, and hormonal status in healthy postmenopausal women. Maturitas. 2002;43:207-214.
166. Hellmann-Blumberg U, Taras TL, Wurz GT, DeGregorio MW. Genotoxic effects of the novel mixed antiestrogen FC-1271a in comparison to tamoxifen and toremifene. Breast Cancer Res Treat. 2000;60:63-70.
167. Draper MW, Flowers DE, Huster WJ, et al. A controlled trial of raloxifene (LY139481) HCl: impact on bone turnover and serum lipid profile in healthy postmenopausal women. J Bone Miner Res. 1996;11:835-842.
168. Gluck O, Maricic M. Raloxifene: recent information on skeletal and non-skeletal effects. Curr Opin Rheumatol. 2002;14:429-432.
169. Licata AA, Ciaccia AV, Wong M, Draper MW. Raloxifene: a new choice for treating and preventing osteoporosis. Cleveland Clin J Med. 2000;67:273-280.
170. Delmas PD, Bjarnason NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med. 1997;337:1641-1647.
171. Johnston CC Jr, Bjarnason NH, Cohen FJ, et al. Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women: three-year data from 2 double-blind, randomized, placebo-controlled trials. Arch Intern Med. 2000;160:3444-3450.
172. Jolly EE, Bjarnason NH, Neven P, et al. Effective prevention of osteoporosis and long-term uterine safety in early postmenopausal women taking raloxifene. Menopause. 2003, in press.
173. Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA. 1999;281:2189-2197.
174. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA. 1999;282:637-645.
175. Barrett-Connor E, Grady D, Sashegyi A, et al. Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA. 2002;287:847-857.
176. Anderson PW, Cox DA, Sashegyi A, et al. Effects of raloxifene and hormone replacement therapy on markers of serum atherogenicity in healthy postmenopausal women. Maturitas. 2001;39:71-77.
177. Walsh BW, Cox DA, Sashegyi A, et al. Role of tumor necrosis factor-alpha and interleukin-6 in the effects of hormone replacement therapy and raloxifene on C-reactive protein in postmenopausal women. Am J Cardiol. 2001;88:825-828.
178. DeLeo V, la Marca A, Morgante G, et al. Randomized control study of the effects of raloxifene on serum lipids and homocysteine in older women. Am J Obstet Gynecol. 2001;184:350-353.
179. Christodoulakos G, Panoulis C, Kouskouni E, et al. Effects of estrogen-progestin and raloxifene therapy on nitric oxide, prostacyclin and endothelin-1 synthesis. Gynecol Endocrinol. 2002;16:9-17.
180. Saitta A, Altavilla D, Cucinotta D, et al. Randomized, double-blind, placebo-controlled study on effects of raloxifene and hormone replacement therapy on plasma no concentrations, endothelin-1 levels, and endothelium-dependent vasodilation in postmenopausal women. Arteriosclerosis Thromb Vasc Biol. 2001;21:1512-1519.
181. Post MS, van der Mooren MJ, van Baal WM, et al. Raloxifene reduces impedance to flow within the uterine artery in early postmenopausal women: a 2-year randomized, placebo-controlled, comparative study. Am J Obstet Gynecol. 2001;185:557-562.
182. Cagnacci A, Arangino S, Renzi A, et al. Raloxifene does not influence flow-mediated endothelium-dependent and endothelium-independent vasodilatation of osteopenic postmenopausal women. Am J Obstet Gynecol. 2003;188:313-317.
183. Sarrel PM, Nawaz H, Chan W, et al. Raloxifene and endothelial function in healthy postmenopausal women. Am J Obstet Gynecol. 2003;188:304-309.
184. Christodoulakos GE, Lambrinoudaki IV, Vourtsi AD, et al. Mammographic changes associated with raloxifene and tibolone therapy in postmenopausal women: a prospective study. Menopause. 2002;9:110-116.
185. Cauley JA, Norton L, Lippman ME, et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. [Erratum appears in Breast Cancer Res Treat. 2001;672:191]. Breast Cancer Res Treat. 2001;65:125-134.
186. Delmas PD, Ensrud KE, Adachi JD, et al. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab. 2002;87:3609-3617.
187. Sarkar S, Mitlak BH, Wong M, et al. Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. J Bone Miner Res. 2002;17:1-10.
188. Prestwood KM, Gunness M, Muchmore DB, et al. A comparison of the effects of raloxifene and estrogen on bone in postmenopausal women. J Clin Endocrinol Metab. 2000;85:2197-2202.
189. Ott SM, Oleksik A, Lu Y, et al. Bone histomorphometric and biochemical marker results of a 2-year placebo-controlled trial of raloxifene in postmenopausal women. J Bone Miner Res. 2002;17:341-348.
190. Boss SM, Huster WJ, Neild JA, et al. Effects of raloxifene hydrochloride on the endometrium of postmenopausal women. Am J Obstet Gynecol. 1997;177:1458-1464.
191. Goldstein SR, Scheele WH, Rajagopalan SK, et al. A 12-month comparative study of raloxifene, estrogen, and placebo on the postmenopausal endometrium. Obstet Gynecol. 2000;95:95-103.
192. Johnson S, Zhou L, Taylor YL, et al: Effect of 4 year raloxifine therapy on endometrail hyperplasi and endometrial cancer in postmenopausal women with osteoporosis. Menopause. 2001;8:22.
193. Baker VL, Draper M, Paul S, et al. Reproductive endocrine and endometrial effects of raloxifene hydrochloride, a selective estrogen receptor modulator, in women with regular menstrual cycles. J Clin Endocrinol Metab. 1998;83:6-13.
194. Goldstein SR. An update on non-uterine gynaecological effects on raloxifene. EJC. 2002;38(Suppl 6):S65-S66.
195. Goldstein S, Johnson S, Ciaccia A, et al. Incidence of urinary incontinence in postmenopausal women particiapting in a placebo-controlled trial of raloxifene and estrogen. Menopause. 2001;8:24.
196. Goldstein SR, Neven P, Zhou L, et al. Raloxifene's effect on frequency of surgery for pelvic floor relaxation. Obstet Gynecol. 2001;98:91-96.
197. Freedman M, San Martin J, O'Gorman J, et al. Digitized mammography: a clinical trial of postmenopausal women randomly assigned to receive raloxifene, estrogen, or placebo. J Natl Cancer Inst. 2001;93:51-56.
198. Littleton-Kearney MT, Ostrowski NL, Cox DA, et al. Selective estrogen receptor modulators: tissue actions and potential for CNS protection. [Review]. CNS Drug Reviews. 2002;8:309-330.
199. Yaffe K, Krueger K, Sarkar S, et al. Cognitive function in postmenopausal women treated with raloxifene. N Engl J Med. 2001;344:1207-1213.
200. Davies GC, Huster WJ, Lu Y, et al. Adverse events reported by postmenopausal women in controlled trials with raloxifene. Obstet Gynecol. 1999;93:558-555.
201. Cohen FJ, Lu Y. Characterization of hot flashes reported by healthy postmenopausal women receiving raloxifene or placebo during osteoporosis prevention trials. Maturitas. 2000;34:65-73.
202. Reindollar R, Koltun W, Parsons A, et al. Effects of oral raloxifene on serum estradiol levels and other markers of estrogenicity. Fertil Steril. 2002;78:469-472.
203. Hsu SH, Cheng WC, Jang MW, Tsai KS. Effects of long-term use of raloxifene, a selective estrogen receptor modulator, on thyroid function test profiles. Clin Chem. 2001;47:1865-1867.
204. Neven P, Goldstein SR, Ciaccia AV, et al. The effect of raloxifene on the incidence of ovarian cancer in postmenopausal women. Gynecol Oncol. 2002;85:388-390.
205. Suh N, Glasebrook AL, Palkowitz AD, et al. Arzoxifene, a new selective estrogen receptor modulator for chemoprevention of experimental breast cancer. Cancer Res. 2001;61:8412-8415.
206. Chan S. A review of selective estrogen receptor modulators in the treatment of breast and endometrial cancer. Semin Oncol. 2002;29:129-133.
207. Fabian CJ, Anderson J, Chamberlain C, et al. Change in serum dehydroepiandrosterone, testosterone, insulin-like growth factor-1, and osteocalcin levels with the third generation selective estrogen receptor modulator arzoxifene (LY353381-HCl). Breast Cancer Res Treat. 2001;69:225.
208. Ke HZ, Qi H, Crawford DT, et al. Lasofoxifene (CP-336,156), a selective estrogen receptor modulator, prevents bone loss induced by aging and orchidectomy in the adult rat. Endocrinology. 2000;141:1338-1344.
209. Singh MM. Centchroman, a selective estrogen receptor modulator, as a contraceptive and for the management of hormone-related clinical disorders. Med Res Rev. 2001;21:302-347.
210. Skrumsager BK, Kiehr B, Pedersen PC, et al. Levormeloxifene: safety, pharmacodynamics and pharmacokinetics in healthy postmenopausal women following single and multiple doses of a new selective oestrogen receptor modulator. Br J Clin Pharmacol. 2002;53:284-295.
211. Alexandersen P, Riis BJ, Stakkestad JA, et al. Efficacy of levormeloxifene in the prevention of postmenopausal bone loss and on the lipid profile compared to low-dose hormone replacement therapy. J Clin Endocrinol Metab. 2001;86:755-760.
212. Goldstein SR, Nanavati N. Adverse events that are associated with the selective estrogen receptor modulator levormeloxifene in an aborted phase III osteoporosis treatment study. Am J Obstet Gynecol. 2002;187:521-527.
213. Labrie F, Labrie C, Belanger A, et al. EM-652 (SCH 57068), a third-generation SERM acting as pure antiestrogen in the mammary gland and endometrium. J Steroid Biochem Mol Biol. 1999;69:51-84.
214. Labrie F, Labrie C, Belanger A, et al. EM-652 (SCH57068), a pure SERM having complete antiestrogenic activity in the mammary gland and endometrium. J Steroid Biochem Mol Biol. 2001;79:213-225.
215. Labrie F, Champagne P, Labrie C, et al. Response to the orally active specific antiestrogen EM-800 (SCH-57050) in tamoxifen-resistant breast cancer. Breast Cancer Res Treat. 1997;46:S3.
216. Howell A, Howell SJ, Clarke R, Anderson E. Where do selective estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs) now fit into breast cancer treatment algorithms? J Steroid Biochem Mol Biol. 2001;79:227-237.
217. Sorbera LA, Castaner J, Silvestre JS. Pipendoxifene. Drugs of the Future. 2002;27:942-947.
218. Cotreau MM, Stonis L, Dykstra KH, et al. Multiple-dose, safety, pharmacokinetics, and pharmacodynamics of a new selective estrogen receptor modulator, ERA-923, in healthy postmenopausal women. J Clin Pharm. 2002;42:157-165.
219. Ronkin S, Clarke L, Boudes P, Constantine G. TSE-424, a novel tissue selective estrogen, reduces biochemical indices of bone metabolism in a dose-related fashion. J Bone Min Res. 2001;16(Suppl.):S413.
220. Komm BS, Lyttle CR. Developing a SERM: stringent preclinical selection criteria leading to an acceptable candidate (WAY-140424) for clinical evaluation. Ann NY Acad Sci. 2001;949:317-326.
221. Robertson JF. Estrogen receptor down-regulators: new antihormonal therapy for advanced breast cancer. Clin Ther. 2002;24:A17-30.
222. Cheung KL, Robertson. JF. Fulvestrant. Expert Opin Investig Drugs. 2002;11:303-308.
223. Wardley AM. Fulvestrant: a review of its development, pre-clinical and clinical data. Int J Clin Pract. 2002;56:305-309.
224. Howell A, Osborne CK, Morris C, Wakeling AE. ICI 182,780 (Faslodex): development of a novel, "pure" antiestrogen. Cancer. 2000;89:817-825.
225. Osborne CK, Pippen J, Jones SE, et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol. 2002;20:3386-3395.
226. Walsh BW. The effects of estrogen and selective estrogen receptor modulators on cardiovascular risk factors. Ann NY Acad Sci. 2001;949:163-167.